27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of 10x Genomics (NASDAQ:TXG) remained unaffected after the company reported Q1 results.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Quarterly Results
Earnings per share rose 186.96% over the past year to $0.66, which beat the estimate of $0.50.
Revenue of $231,200,000 higher by 34.42% from the same period last year, which missed the estimate of $232,000,000.
Guidance
10x Genomics hasn't issued any earnings guidance for the time being.
10x Genomics hasn't issued any revenue guidance for the time being.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
How To Listen To The Conference Call
Date: May 13, 2021
Time: 09:00 AM
ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=mn0CsRHj
Recent Stock Performance
Company's 52-week high was at $203.25
52-week low: $72.04
Price action over last quarter: down 7.08%
Company Overview
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.